XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Cover - shares
 3 Months Ended
Mar. 31, 2024
May 15, 2024
Document Type 10-Q/A  
Amendment Flag true  
Amendment Description As described in Item 4.02 of the Company’s Form 8-K filed with the SEC on November 14, 2024, we determined that the Company’s deferred commission payable, previously classified as a long term liability, should have been classified as a current liability in the Company’s March 31, 2024 and June 30, 2024 condensed consolidated balance sheets.Restatement Background  On November 12, 2024, the Audit Committee of the Board of Directors of the Company, after discussions with the Company’s management and its independent registered public accounting firm, determined that the Company’s unaudited financial statements included in each of the Company’s Quarterly Reports on Form 10-Q for the periods ending March 31, 2024 (the “Q1 2024 Form 10-Q”) and June 30, 2024 (the “Q2 2024 Form 10-Q”), together (the “Financial Statements” or “Affected Periods”), filed with the SEC on May 15, 2024, and August 12, 2024, respectively, as well as the relevant portions of any communication which describe or are based on the Financial Statements, should no longer be relied upon.   In connection with the preparation of the Company’s financial statements for the three and nine months ended September 30, 2024, the Company’s management determined that a reclassification was necessary in its previously issued unaudited financial statements, relating solely to the balance sheet, as of March 31, 2024. It was determined that the Company’s deferred commission payable, previously classified as a long term liability, should have been classified as a current liability in the March 31, 2024 condensed consolidated balance sheet. Such reclassification did not have any impact on the total liabilities owed by the Company as of March 31, 2024.   Items Amended in this Filing   This Form 10-Q/A amends and restates the following items included in the original form 10-Q as appropriate to reflect the Restatement and revision of the relevant periods:     ● Part I, Item 1-Financial Statements (Unaudited)   The Company is including with this Form 10-Q/A currently dated certifications of the Company’s Chief Executive Officer and Interim Chief Financial Officer (Exhibits (Exhibits 31.1, 31.2, 32.1, and 32.2).   Except as discussed above and as further described in Note 2 to the Condensed Consolidated Financial Statements in this Form 10-Q/A, the Company has not modified or updated the disclosures presented in the original form 10-Q to reflect events that occurred at a later date or facts that subsequently became known to the Company. Accordingly, forward-looking statements included in this Amendment No.1 may represent management’s views as of the original form 10-Q and should not be assumed to be accurate as of any date thereafter. Disclosures not affected by the Restatement are unchanged and reflect the disclosures made at the time of the original filing. Accordingly, this amended form 10-Q should be read in conjunction with our filings with the SEC subsequent to the date on which we filed the original filing with the SEC.    
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2024  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2024  
Current Fiscal Year End Date --12-31  
Entity File Number 001-41245  
Entity Registrant Name CONDUIT PHARMACEUTICALS INC.  
Entity Central Index Key 0001896212  
Entity Tax Identification Number 87-3272543  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 4581 Tamiami Trail North,  
Entity Address, Address Line Two Suite 200  
Entity Address, City or Town Naples  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 34103  
City Area Code (646)  
Local Phone Number -491-9132  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   73,829,536
Common Stock, par value $0.0001 per share    
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol CDT  
Security Exchange Name NASDAQ  
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50    
Title of 12(b) Security Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50  
Trading Symbol CDTTW  
Security Exchange Name NASDAQ